Combined etoposide, ifosfamide, and cisplatin in the treatment of patients with advanced thymoma and thymic carcinoma: an intergroup trial.

@article{Loehrer2001CombinedEI,
  title={Combined etoposide, ifosfamide, and cisplatin in the treatment of patients with advanced thymoma and thymic carcinoma: an intergroup trial.},
  author={Patrick J. Loehrer and M R Jiroutek and Seena Aisner and Joseph Aisner and Mark D Green and Charles R. Thomas and Robert R Livingston and David H. Johnson},
  journal={Cancer},
  year={2001},
  volume={91 11},
  pages={2010-5}
}
BACKGROUND Patients with thymic tumors (thymoma and thymic carcinoma) are known to respond to a variety of chemotherapeutic agents, including single-agent ifosfamide and cisplatin with etoposide. The purpose of this trial was to evaluate the response rate, progression free survival, overall survival, and toxicity of combined etoposide, ifosfamide, and cisplatin (VIP) in patients with advanced thymoma and thymic carcinoma. METHODS From July 1995 through February 1997, 34 patients with advanced… CONTINUE READING
48 Citations
0 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 48 extracted citations

Similar Papers

Loading similar papers…